Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5

Human Gene Therapy

Volumn 24, Issue 3, 2013, Pages 245-258

  Maier, Dawn A ^a   Brennan, Andrea L ^a   Jiang, Shuguang ^a   Binder Scholl, Gwendolyn K ^a,c   Lee, Gary ^b   Plesa, Gabriela ^a   Zheng, Zhaohui ^a   Cotte, Julio ^a   Carpenito, Carmine ^a,d   Wood, Travis ^b   Kaye Spratt, S ^b   Ando, Dale ^b   Gregory, Philip ^b   Holmes, Michael C ^b   Perez, Elena E ^a,e   Riley, James L ^a   Carroll, Richard G ^a   June, Carl H ^a   Levine, Bruce L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SANGAMO BIOSCIENCES INC   (United States)

^c Adaptimmune Ltd   (United Kingdom)

^d LONZA   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD28 ANTIGEN; CD3 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; TUMOR NECROSIS FACTOR ALPHA; ZINC FINGER NUCLEASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY TEST; DNA MODIFICATION; DRUG CYTOTOXICITY; DRUG SAFETY; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE TRANSFER; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSIENT EXPRESSION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRUSES, HUMAN; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD28; ANTIGENS, CD3; DNA RESTRICTION ENZYMES; FEMALE; GENETIC VECTORS; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MICE; PHENOTYPE; RECEPTORS, CCR5; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; ZINC FINGERS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84875420616     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.172     Document Type: Article

References (78)

1. Allers, K., Hutter, G., Hofmann, J., et al. (2011). Evidence for the cure of HIV infection by CCR5{Delta}32/{Delta}32 stem cell transplantation. Blood. 117, 2791-2799.
2. Carrington, M., Dean, M., Martin, M.P., and O'Brien, S.J. (1999). Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum. Mol. Genet. 8, 1939-1945.
3. Chen, Z., Ahonen, M., Hamalainen, H., et al. (2002). Highefficiency gene transfer to primary T lymphocytes by recombinant adenovirus vectors. J. Immunol. Methods. 260, 79-89.
4. Cho, H.I., Kim, H.J., Oh, S.T., and Kim, T.G. (2003). In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine. 22, 224-236.
5. Cohen O.J., et al. (1997). Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected longterm nonprogressors. J. Clin. Invest. 100, 1581-1589.
6. Connors, M., et al. (1997). HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat. Med. 3, 533-540.
7. Dropulic, B., and June, C.H. (2006). Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Hum. Gene Ther. 17, 577-588.
8. Eugen-Olsen, J., et al. (1997). Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS. 11, 305-310.
9. Gabriel, R., et al. (2011). An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat. Biotechnol. 29, 816-823.
10. Gagne, K., et al. (2000). Highly altered V beta repertoire of T cells infiltrating long-term rejected kidney allografts. J. Immunol. 164, 1553-1563.
11. Garcia, S., Dadaglio, G., and Gougeon, M.L. (1997). Limits of the human-PBL-SCID mice model: severe restriction of the V beta T-cell repertoire of engrafted human T cells. Blood. 89, 329-336.
12. Gea-Banacloche, J.C., et al. (1998). Progression of human immunodeficiency virus disease is associated with increasing disruptions within the CD4+ T cell receptor repertoire. J. Infect. Dis. 177, 579-585.
13. Gea-Banacloche, J.C., et al. (2000). Longitudinal changes in CD4+ T cell antigen receptor diversity and naive/memory cell phenotype during 9 to 26 months of antiretroviral therapy of HIV-infected patients. AIDS Res. Hum. Retroviruses 16, 1877-1886.
14. Gorochov, G., et al. (1998). Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat. Med. 4, 215-221.
15. Guillet, M., Brouard, S., Gagne, K., et al. (2002). Different qualitative and quantitative regulation of V beta TCR transcripts during early acute allograft rejection and tolerance induction. J. Immunol. 168, 5088-5095.
16. Hacein-Bey-Abina, S., et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419.
17. Hami, L.S., Green, C., Leshinsky, N., et al. (2004). GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL. Cytotherapy 6, 554-562.
18. Hollyman, D., et al. (2009). Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32, 169-180.
19. Holt, N., et al. (2010). Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28, 839-847.
20. Horwitz, E.M., Gordon, P.L., Koo, W.K., et al. (2002). Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc. Natl. Acad. Sci. U.S.A. 99, 8932-8937.
21. Hurez, V., Dzialo-Hatton, R., Oliver, J., et al. (2002). Efficient adenovirus-mediated gene transfer into primary T cells and thymocytes in a new coxsackie/adenovirus receptor transgenic model. BMC. Immunol. 3, 4.
22. Hutter, G., and Thiel, E. (2011). Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS 25, 273-274.
23. Hutter, G., et al. (2009). Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692-698.
24. Ishikawa, F., et al. (2005). Development of functional human blood and immune systems in NOD/SCID/IL2 receptor c chainnull mice. Blood. 106, 1565-1573.
25. Ito, M., et al. (2002). NOD/SCID/c(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 100, 3175-3182.
26. June, C., and Levine, B. (2012). Blocking HIV's attack. Sci. Am. 306, 54-59.
27. Jung, D., Neron, S., Drouin, M., and Jacques, A. (2005). Efficient gene transfer into normal human B lymphocytes with the chimeric adenoviral vector Ad5/F35. J. Immunol. Methods. 304, 78-87.
28. Kim, Y.G., Cha, J., and Chandrasegaran, S. (1996). Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. U.S.A. 93, 1156-1160.
29. Kumar, P., et al. (2008). T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell. 134, 577-586.
30. Laport, G.G., et al. (2003). Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 102, 2004-2013.
31. Leen, A.M., Sili, U., Savoldo, B., et al. (2004). Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirusspecific cytotoxic T lymphocytes for therapeutic applications. Blood. 103, 1011-1019.
32. Levine, B.L., Ueda, Y., Craighead, N., et al. (1995). CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Int. Immunol. 7, 891-904.
33. Levine, B. L., et al. (1996). Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272, 1939-1943.
34. Levine, B.L., Bernstein, W.B., Connors, M., et al. (1997). Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. Journal of Immunology 159, 5921-5930.
35. Levine, B.L., Cotte, J., Small, C.C., et al. (1998). Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J. Hematother. 7, 437-448.
36. Levine, B.L., et al. (2002). Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat. Med. 8, 47-53.
37. Levine, B. L., et al. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 103, 17372-17377.
38. Li, M.J., Kim, J., Li, S., et al. (2005). Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 12, 900-909.
39. Lin, C., Chen, S., Yang, L., et al. (2007). Evaluation of TCR Vbeta subfamily T cell expansion in NOD/SCID mice transplanted with human cord blood hematopoietic stem cells. Hematology 12, 325-330.
40. Liu, R., et al. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377.
41. Liu, P.Q., et al. (2001). Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J. Biol. Chem. 276, 11323-11334.
42. Lu, Z.Z., Ni, F., Hu, Z.B. et al. (2006). Efficient gene transfer into hematopoietic cells by a retargeting adenoviral vector system with a chimeric fiber of adenovirus serotype 5 and 11p. Exp. Hematol. 34, 1171-1182.
43. Mackensen, A., Drager, R., Schlesier, M., et al. (2000). Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol.Immunother. 49, 152-156.
44. Martinon, F., Michelet, C., Peguillet, I., et al. (1999). Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy. AIDS 13, 185-194.
45. Mosier, D.E., Picchio, G.R., Kirven, M.B., et al. (1992). EBVinduced human B cell lymphomas in hu-PBL-SCID mice. AIDS Res. Hum. Retroviruses. 8, 735-740.
46. Nervi, B., et al. (2007). Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. Exp. Hematol. 35, 1823-1838.
47. Nilsson, M., Ljungberg, J., Richter, J., et al. (2004). Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J. Gene Med. 6, 631-641.
48. Nwanegbo, E., Vardas, E., Gao, W., et al. (2004). Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab Immunol. 11, 351-357.
49. Pannetier, C., Even, J., and Kourilsky, P. (1995). T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol. Today 16, 176-181.
50. Pantaleo, G., and Koup, R.A. (2004). Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10, 806-810.
51. Paxton, W.A., et al. (1996). Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat. Med. 2, 412-417.
52. Pelz, O., Wu, M., Nikolova, T., et al. (2005). Duplex polymerase chain reaction quantification of human cells in a murine background. Stem Cells. 23, 828-833.
53. Perez, E.E., et al. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26, 808-816.
54. Porter, D.L., et al. (2006). A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 107, 1325-1331.
55. Powell Jr., D.J., Brennan, A.L., Zheng, Z., et al. (2009). Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. Cytotherapy. 11, 923-935.
56. Quillent, C., et al. (1998). HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet. 351, 14-18.
57. Rahman, S.H., Maeder, M.L., Joung, J.K., and Cathomen, T. (2011). Zinc-finger nucleases for somatic gene therapy: the next frontier. Hum. Gene Ther. 22, 925-933.
58. Rapoport, A.P., et al. (2004). Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous. T cells: Bone Marrow Transplant. 33, 53-60.
59. Rapoport, A.P., et al. (2005). Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11, 1230-1237.
60. Rapoport, A.P., et al. (2009). Rapid immune recovery and graftversus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin. Cancer Res. 15, 4499-4507.
61. Rebar, E.J., et al. (2002). Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med. 8, 1427-1432.
62. Sarver, N., and Rossi, J., (1993). Gene therapy: a bold direction for HIV-1 treatment. AIDS Res. Hum. Retroviruses. 9, 483-487.
63. Schroers, R., Hildebrandt, Y., Hasenkamp, J., et al. (2004). Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors. Exp. Hematol. 32, 536-546.
64. Sebille, F., Gagne, K., Guillet, M., et al. (2001). Direct recognition of foreign MHC determinants by naive T cells mobilizes specific Vbeta families without skewing of the complementaritydetermining region 3 length distribution. J. Immunol. 167, 3082-3088.
65. Selvaggi, T.A., Walker, R.E., and Fleisher, T.A. (1997). Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood. 89, 776-779.
66. Shayakhmetov, D.M., Papayannopoulou, T., Stamatoyannopoulos, G., and Lieber, A. (2000) Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J. Virol. 74, 2567-2583.
67. Shultz, L.D., et al. (2005). Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477-6489.
68. Smith, M.W., Carrington, M., Winkler, C., et al. (1997). CCR2 chemokine receptor and AIDS progression. Nat. Med. 3, 1052-1053.
69. Smith, J., Berg, J.M., and Chandrasegaran, S. (1999). A detailed study of the substrate specificity of a chimeric restriction enzyme. Nucleic Acids Res. 27, 674-681.
70. Snowden, A.W., et al. (2003). Repression of vascular endothelial growth factor A in glioblastoma cells using engineered zinc finger transcription factors. Cancer Res. 63, 8968-8976.
71. Tan, S., et al. (2003). Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity. Proc. Natl. Acad. Sci. U.S.A. 100, 11997-12002.
72. Tuschong, L., Soenen, S.L., Blaese, R.M., et al. (2002). Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum. Gene Ther. 13, 1605-1610.
73. Urnov, F.D., et al. (2005). Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646-651.
74. van Lunzen, J., et al. (2007). Transfer of autologous genemodified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol. Ther. 15, 1024-1033.
75. Verani, A., and Lusso, P. (2002). Chemokines as natural HIV antagonists. Curr. Mol. Med. 2, 691-702.
76. von Laer, D., Hasselmann, S., and Hasselmann, K. (2006). Impact of gene-modified T cells on HIV infection dynamics. J. Theor. Biol. 238, 60-77.
77. Wagar, E.J., Cromwell, M.A., and Shultz, L.D. (2000). Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice. J. Immunol. 165, 518-527.
78. Zhao, Y., et al. (2010). Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70, 9053-9061.